KMDS
E-submission
Search
- Page Path
- HOME > Search
Review Article
- Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
- Ju-Hee Kang
- J Mov Disord. 2016;9(2):89-96. Published online May 25, 2016
- DOI: https://doi.org/10.14802/jmd.16017
- 26,712 View
- 265 Download
- 20 Web of Science
- 20 Crossref
-
Abstract
PDF - Parkinson’s disease (PD) is a neurodegenerative disease with heterogeneous pathological and clinical features. Cognitive dysfunction, a frequent non-motor complication, is a risk factor for poor prognosis and shows inter-individual variation in its progression. Of the clinical studies performed to identify biomarkers of PD progression, the Parkinson’s Progression Markers Initiative (PPMI) study is the largest study that enrolled drug-naïve and very early stage PD patients. The baseline characteristics of the PPMI cohort were recently published. The diagnostic utility of cerebrospinal fluid (CSF) biomarkers, including alpha-synuclein (α-syn), total tau, phosphorylated tau at Thr181, and amyloid β1-42, was not satisfactory. However, the baseline data on CSF biomarkers in the PPMI study suggested that the measurement of the CSF biomarkers enables the prediction of future cognitive decline in PD patients, which was consistent with previous studies. To prove the hypothesis that the interaction between Alzheimer’s pathology and α-syn pathology is important to the progression of cognitive dysfunction in PD, longitudinal observational studies must be followed. In this review, the neuropathological nature of heterogeneous cognitive decline in PD is briefly discussed, followed by a summarized interpretation of baseline CSF biomarkers derived from the data in the PPMI study. The combination of clinical, biochemical, genetic and imaging biomarkers of PD constitutes a feasible strategy to predict the heterogeneous progression of PD.
-
Citations
Citations to this article as recorded by
- Preparing for Parkinson’s disease prevention trials: Current progress and future directions
Sarah Bouhadoun, Aline Delva, Michael A Schwarzschild, Ronald B Postuma
Journal of Parkinson’s Disease.2026; 16(2_suppl): 55. CrossRef - Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson’s Disease
Cameron A. Ryczek, Rhiannon Rivas, Lea Hemphill, Zackary Zanotelli, Nicholas Renteria, Khashayar Dashtipour, Jacob D. Jones
The Journal of Neuropsychiatry and Clinical Neurosciences.2025; 37(2): 131. CrossRef - Highly sensitive biosensor based on IGZO thin-film transistors for detection of Parkinson's disease
Tongzheng Li, Tongying Xu, Zhengyang Yao, Yanan Ding, Guoxia Liu, Fukai Shan
Applied Physics Letters.2023;[Epub] CrossRef - Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease
Joseph Blommer, Toni Pitcher, Maja Mustapic, Erden Eren, Pamela J Yao, Michael P Vreones, Krishna A Pucha, John Dalrymple-Alford, Reza Shoorangiz, Wassilios G Meissner, Tim Anderson, Dimitrios Kapogiannis
Brain.2023; 146(1): 195. CrossRef - Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
John P. Seibyl
Journal of Nuclear Medicine.2023; 64(1): 12. CrossRef - REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study
Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh
Journal of Neurology.2022; 269(9): 4836. CrossRef - Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Thomas Kremer, Kirsten I. Taylor, Juliane Siebourg‐Polster, Thomas Gerken, Andreas Staempfli, Christian Czech, Juergen Dukart, Douglas Galasko, Tatiana Foroud, Lana M. Chahine, Christopher S. Coffey, Tanya Simuni, Daniel Weintraub, John Seibyl, Kathleen L
Movement Disorders.2021; 36(8): 1972. CrossRef - Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis
J. M. Hatcher-Martin, J. L. McKay, A. F. Pybus, B. Sommerfeld, J. C. Howell, F. C. Goldstein, L. Wood, W. T. Hu, S. A. Factor
npj Parkinson's Disease.2021;[Epub] CrossRef - Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model
Mehmet Ozansoy, Muzaffer Beyza Ozansoy, Burak Yulug, Seyda Cankaya, Ertugrul Kilic, Sule Goktekin, Ulkan Kilic
Journal of Clinical Neuroscience.2020; 73: 237. CrossRef - Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology
Maja Malmberg, Tarja Malm, Oskar Gustafsson, Andrea Sturchio, Caroline Graff, Alberto J. Espay, Anthony P. Wright, Samir El Andaloussi, Anders Lindén, Kariem Ezzat
Frontiers in Neuroscience.2020;[Epub] CrossRef - Why would Parkinson’s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses
Jon O. Lauring, Tomohiro Ishizu, Hana H. Kutlikova, Felix Dörflinger, Steven Haugbøl, Helmut Leder, Ron Kupers, Matthew Pelowski
Neuroscience & Biobehavioral Reviews.2019; 100: 129. CrossRef - Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
Tracy R. Melzer, Megan R. Stark, Ross J. Keenan, Daniel J. Myall, Michael R. MacAskill, Toni L. Pitcher, Leslie Livingston, Sophie Grenfell, Kyla-Louise Horne, Bob N. Young, Maddie J. Pascoe, Mustafa M. Almuqbel, Jian Wang, Steven H. Marsh, David H. Mille
Frontiers in Neurology.2019;[Epub] CrossRef - Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Kurt A. Jellinger
Journal of Neural Transmission.2018; 125(4): 615. CrossRef - Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study
George D. Vavougios, Triantafyllos Doskas, Constantinos Kormas, Karen A. Krogfelt, Sotirios G. Zarogiannis, Leonidas Stefanis
Journal of the Neurological Sciences.2018; 387: 103. CrossRef - Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
Nooshin Abbasi, Bahram Mohajer, Sima Abbasi, Payam Hasanabadi, Amirhussein Abdolalizadeh, Reza Rajimehr
Movement Disorders.2018; 33(3): 431. CrossRef - Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
Mahsa Dolatshahi, Shayan Pourmirbabaei, Aida Kamalian, Amir Ashraf-Ganjouei, Mehdi Yaseri, Mohammad H. Aarabi
Frontiers in Neurology.2018;[Epub] CrossRef - Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study
Manuel Delgado‐Alvarado, Rosalía Dacosta‐Aguayo, Irene Navalpotro‐Gómez, Belén Gago, Ana Gorostidi, Haritz Jiménez‐Urbieta, Ana Quiroga‐Varela, Javier Ruiz‐Martínez, Alberto Bergareche, María C. Rodríguez‐Oroz
Movement Disorders.2018; 33(11): 1809. CrossRef - Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases
Ji-Young Choi, Sujin Kim, Hyo-Bum Kwak, Dong-Ho Park, Jae-Hyoung Park, Jeong-Seon Ryu, Chang-Shin Park, Ju-Hee Kang
International Neurourology Journal.2017; 21(2): 83. CrossRef - Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum, Jianjun Chang, Jaegwon Chung, Chelsea Caspell-Garcia, Peggy Taylor, Brit Mollenhauer, Michael G. Schlossmacher, Larry Ereshefsky, Mark Yen, Catherine Kopil, Mark Frasier, Kenneth Marek, Vicki S.
Journal of Neuroinflammation.2017;[Epub] CrossRef - Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias
Julie A Fields
Archives of Clinical Neuropsychology.2017; 32(7): 786. CrossRef
- Preparing for Parkinson’s disease prevention trials: Current progress and future directions
First
Prev
